跳至主要内容
临床试验/CTRI/2020/11/028833
CTRI/2020/11/028833尚未招募2/3 期

Single arm clinical study to evaluate the effect of nagbala kshirpak in management of essential hypertension

Samkit Shah1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2020年9月11日最近更新:

试验速览

阶段
2/3 期
状态
尚未招募
发起方
入组人数
40
试验地点
1
主要终点
Nagbala kshirpaka is effective in the management of essential hypertension.

研究概览

简要总结

The aim of the study is to see the effectiveness of nagbala kshirpak in management of essential hypertension. The study will be conducted with 40 patients showing signs and symptoms of essential hypertension,they will be administered with nagbala kshirpak twice a day for 21 days and follow up will be done on 7,14& 21 days and conclusion will be drawn on the basis of proper statistical methods

研究设计

研究类型
Interventional
分配方式
Computer generated randomization
盲法
Open Label

入排标准

年龄范围
18.00 Year(s) 至 99.00 Year(s)(—)
性别
All

入选标准

  • Systolic Blood Pressure: less than 170 mm of Hg more than or equal to 140 mm of Hg. 2)Diastolic Blood Pressure: less than or equal to 110 mm of Hg or More than 90 mm of Hg. 3)Patient willing to enroll in the research & to sign the consent form.

排除标准

  • Patient who have past history of atrial fibrillation, acute coronary syndrome, myocardial infarction, stroke or right ventricular hypertrophy, left ventricular hypertrophy, severe arrhythmia in last 6 months.
  • Symptomatic patients with clinical features of early heart failure.
  • Secondary hypertension.
  • Women who are pregnant and lactating or on estrogen replacement therapy.
  • Alcoholics and drug abusers.
  • Accelerated and malignant hypertension.

结局指标

主要结局

Nagbala kshirpaka is effective in the management of essential hypertension.

时间窗: 21 days study with 3 follow ups (0,7,14,21 days)

次要结局

未报告次要终点

研究者

发起方
Samkit Shah
申办方类型
Other [Self ]

研究点 (1)

Loading locations...

相似试验